Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Zhejiang Jingxin Pharmaceutical Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single matter is being handled by 1 distinct examiner within 1 distinct art unit. The prosecution is currently focused on this lone active case, which represents the entirety of the company's pending workload at the office. With only 1 pending office action, the applicant can dedicate all resources to this specific matter.
CHANDRAKUMAR, NIZAL S is the busiest examiner, responsible for the 1 pending office action. Because there is only 1 distinct examiner and 1 distinct art unit involved, the prosecution strategy is highly concentrated. Practitioners can focus their efforts entirely on the requirements and preferences of this single examiner within the Biotechnology & Pharmaceuticals sector, as there are no other concurrent office actions to manage. This 1 to 1 ratio between pending actions and examiners ensures a direct line of communication with the office for the current portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 1 | 72.7% | +18.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18724209 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | CHANDRAKUMAR, NIZAL S | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18724209 | FUSED BICYCLIC HETEROARYL AMIDE COMPOUND AS PROTEIN AGGREGATION INHIBITOR | CHANDRAKUMAR, NIZAL S | 1625 | §112 | Non-Final OA | — | Pending | Jun 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Jingxin Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nizal S Chandrakumar has the most, with 1 of Zhejiang Jingxin Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
